Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 8/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | LGMN | Q99538 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506280 | 0.88 | CETP (0.47) | CETPPDK2KMT2AALDH1A1MEN1 | |
| SCHEMBL4491971 | 0.88 | CETP (0.47) | CETPPDK2LGMNL3MBTL1 | |
| SCHEMBL4500614 | 0.83 | CETP (0.61) | CETP | |
| SCHEMBL1587600 | 0.83 | CETP (0.49) | CETPPDK2LGMNL3MBTL1 | |
| SCHEMBL132026 | 0.83 | CETP (0.45) | CETPL3MBTL1KMT2AMEN1 | |
| SCHEMBL4493367 | 0.81 | CETP (0.43) | CETPPDK2KMT2AALDH1A1MEN1 | |
| SCHEMBL1587680 | 0.79 | CETP (0.44) | CETPPDK2L3MBTL1 | |
| SCHEMBL4500113 | 0.79 | CETP (0.47) | CETPPDK2KMT2AALDH1A1MEN1 | |
| SCHEMBL4490319 | 0.79 | CETP (0.45) | CETPPDK2KMT2AALDH1A1MEN1 | |
| SCHEMBL129898 | 0.78 | CETP (0.43) | CETPPDK2L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885PDK2 4233/4885LGMN 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.